Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.
IPO Year: 2016
Exchange: NYSE
Website: kadmon.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/14/2021 | $13.00 → $9.50 | Buy → Neutral | Mizuho |
| 9/9/2021 | $10.00 → $9.50 | Buy → Hold | Jefferies |
| 7/19/2021 | $8.00 → $9.00 | Outperform | Oppenheimer |
NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities relating to the potential regulatory approval of belumosudil for chronic graft-versus-host disease and lead the Company's clinical team to advance the development of additional product candidates. Dr. Cooper succeeds John Ryan, M.D., Ph.D., who will remain with the Company and transition to the role of Executive Medical Director, Clinical and Regulatory Development, where he will continue to advise on c
Mizuho downgraded Kadmon Holdings from Buy to Neutral and set a new price target of $9.50 from $13.00 previously
Jefferies downgraded Kadmon Holdings from Buy to Hold and set a new price target of $9.50 from $10.00 previously
Oppenheimer reiterated coverage of Kadmon Holdings with a rating of Outperform and set a new price target of $9.00 from $8.00 previously
UBS initiated coverage of Kadmon Holdings with a rating of Buy and set a new price target of $9.00
Raymond James reiterated coverage of Kadmon with a rating of Outperform and set a new price target of $10.00 from $9.00 previously
Raymond James reiterated coverage of Kadmon Holdings with a rating of Outperform and set a new price target of $10.00 from $9.00 previously
HC Wainwright resumed coverage of Kadmon with a rating of Buy and set a new price target of $25.00
Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton's expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programsDevelopment to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizuresOvid to invest $10 million in preferred equity in Graviton and will fund development programsTransaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sales NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancer's (SITC 2021) 36th Annual Meeting, taking place virtually November 10 - 14, 2021.Details of the presentations are outlined below.Poster PresentationTitle: Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in metastatic and advanced solid tumorsTimes: Friday, November 12, 2021 - Sunday, November 14, 2021, 7:00 a.m. - 5:00 p.m.
Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapyPARIS, FRANCE and NEW YORK, NY / ACCESSWIRE / September 8, 2021 / Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. (NASDAQ:KDMN) a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs. The acquisition supports Sanofi's strategy to continue to grow its General Medicines core assets and will immediately add Rezurock™ (belumosudil) to its transplant
Sanofi to acquire Kadmon to further strengthen growth of transplant business Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy PARIS and NEW YORK – September 8, 2021 – Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. (NASDAQ:KDMN) a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs. The acquisition supports Sanofi's strategy to continue to grow its General Medicines core assets and will
NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets is now commercially available for shipment to prescribed patients in the United States. REZUROCK was approved on July 16, 2021 by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.REZUROCK is available through a network of authorized specialty pharmacies and distributors. Amber Specialty Pharmacy, Biologics by McKesson and Onco360 Oncology Pharmacy, the approved speci
NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021."The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living with cGVHD. REZUROCK represents a paradigm shift in the cGVHD treatment landscape by uniquely addressing both the immune and fibrotic components of the disease," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month."Dr. Waksal added, "Our momentum continues as we advance our portfolio of p
NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the National Comprehensive Cancer Network® (NCCN) added REZUROCKTM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation (HCT) in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease (GVHD). The NCCN Guidelines in the United States now include REZUROCK with a Category 2A designation as a suggested systemic agent for steroid-refractory chronic GVHD."The rapid inclusion of REZUROCK into the NCCN guidelines shortly after full FDA approval validates the potential clinical impact of REZUR
- REZUROCK is approved by the U.S. FDA for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy -NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that data from the pivotal ROCKstar clinical trial of REZUROCK™ (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) were published in the journal Blood. The ROCKstar data served as the basis for the Company's New Drug Application (NDA) for REZUROCK for the treatment of cGVHD, which was granted full approval by the U.S. Food and Drug Administration (FDA) on July 16, 2021 for the treatment of adu
- REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy -- Kadmon to Host Conference Call on Monday, July 19, 2021 at 8:00 a.m. ET -NEW YORK, NY / ACCESSWIRE / July 16, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved REZUROCK™ (belumosudil) 200 mg once daily (QD) for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. The FDA granted Breakthrough Therapy designation and Priority Review for RE
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following
NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021."The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living with cGVHD. REZUROCK represents a paradigm shift in the cGVHD treatment landscape by uniquely addressing both the immune and fibrotic components of the disease," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month."Dr. Waksal added, "Our momentum continues as we advance our portfolio of p
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021."We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA goal date of August 30, 2021. Labeling discussions with the FDA are progressing and we believe that belumosudil, if approved, will serve a critical, unmet need for patients with cGVHD," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "In addition, we are exploring the therapeutic potential of belumosudil in systemic sclerosis, a disease with similar manifestations to cGVHD. We continue to
NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020. "With the acceptance of Kadmon's new drug application for belumosudil in cGVHD in hand, we are preparing for our potential commercial launch in light of our May 30th PDUFA date," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We are leveraging our existing commercial infrastructure and have thus nearly completed the scale-up required to launch belumosudil, if approved. We continue to seek to understand the needs of cGVHD patients in key transplant centers throu
SC 13D - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G - Kadmon Holdings, Inc. (0001557142) (Subject)
SC 13G - Kadmon Holdings, Inc. (0001557142) (Subject)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
15-12B - Kadmon Holdings, Inc. (0001557142) (Filer)
EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)
EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)
POS AM - Kadmon Holdings, Inc. (0001557142) (Filer)
S-8 POS - Kadmon Holdings, Inc. (0001557142) (Filer)
S-8 POS - Kadmon Holdings, Inc. (0001557142) (Filer)
8-K - Kadmon Holdings, Inc. (0001557142) (Filer)
S-8 POS - Kadmon Holdings, Inc. (0001557142) (Filer)
POS AM - Kadmon Holdings, Inc. (0001557142) (Filer)
S-8 POS - Kadmon Holdings, Inc. (0001557142) (Filer)